Is DOSE.CN overvalued or undervalued?

DOSE.CN currently has a P/E ratio of -4.20. Relative to the sector average of 21.40, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Rapid Dose Therapeutics Corp. stock?

Rapid Dose Therapeutics Corp. trades on CNQ. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of DOSE.CN?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying DOSE.CN protect my money against local inflation?

Many investors in Latin America buy international stocks like DOSE.CN to protect their purchasing power. Because DOSE.CN is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy DOSE.CN shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is DOSE.CN a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well DOSE.CN diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksDOSE.CN

Rapid Dose Therapeutics Corp.

CA$0.10+CA$0.00+0.00%

CNQ / CAD

Market cap

CA$14M

P/E

-4.2

EPS (TTM)

CA$-0.02

Dividend yield

0.00%

Beta

-0.85

1Y return

-41.18%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$1M2022

$526,0812023

$750,9852024

$1M2025

$2M2026

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity-0.77Low
Current ratio0.04
Cash ratio0.00
Net margin-123.1%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

DOSE.CN-4.2
Healthcare sector median21.4
S&P 50022.0

Trades about 120% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.07
Price to book-1.81
EPS (TTM)CA$-0.02
Payout ratio0%
FCF yield-1.36%

Range & risk

CA$0.08CA$0.19

Trading in the lower third of its 52-week band

Beta-0.85

Profile

What Rapid Dose Therapeutics Corp. actually does

Rapid Dose Therapeutics Corp., headquartered in Burlington, Canada, is a life sciences enterprise dedicated to developing advanced drug delivery technologies aimed at improving health results and individuals' quality of life. The company's flagship product is QuickStrip/PharmaStrip, an innovative oral, fast-dissolving film designed to swiftly introduce active compounds—such as pharmaceuticals, emulsified oils, and over-the-counter medicines—directly into the bloodstream. They offer specific QuickStrip variants like QuickStrip energy for caffeine delivery, QuickStrip B12 for vitamin B12 supplementation, and QuickStrip sleep for melatonin. Beyond its proprietary products, the firm also delivers comprehensive services encompassing product innovation, manufacturing, and consultation to industries including nutraceuticals, cannabis healthcare, and pharmaceutical production. Rapid Dose Therapeutics maintains a significant research collaboration with McMaster University, focusing on crafting enhanced biopolymer compositions for oral dissolvable thin films and investigating an orally administered vaccine candidate for COVID-19.

CEO

Mark Andrew Upsdell

Employees

Headquarters

Burlington, ON

Founded

2010-02-10

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save DOSE.CN and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

DOSE.CN has a beta of -0.85, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Rapid Dose Therapeutics Corp.